MCOLN1

Mucolipin-1

Score: 0.586 Price: $0.59 Low Druggability Status: active Wiki: MCOLN1
🧠 Neurodegeneration
HYPOTHESES
1
PAPERS
28
KG EDGES
250
DEBATES
0

3D Protein Structure

🧬 MCOLN1 — PDB 5W3S Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability
Low
Score: 0.41
Clinical Stage
Phase I
Target Class
Ion Channel
Safety
0.30
Druggability Analysis
Drug Development0.15
Structural Tractability0.85
Target Class0.85
Safety Profile0.30
Key Metrics
PDB Structures:
38
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Therapeutic Areas:
Mucolipidosis type IV Lysosomal storage disorders Neurodegeneration Autophagy-related diseases Lysosomal dysfunction disorders
Druggability Rationale: MCOLN1 presents moderate druggability (0.60) with strong structural support from 38 PDB structures at 2.1 Å resolution and cryo-EM data, enabling rational design of small molecule modulators. The existence of ML-SA1 as a validated research tool demonstrates feasibility, though ion channels typically present challenges with shallow binding pockets and potential selectivity issues across TRP channel family members.
Mechanism: Small molecule agonists or modulators of lysosomal calcium channel activity
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:
ML-SA1 (research_tool) — Lysosomal storage disorders
Structural Data:
PDB (38) ✓AlphaFold ✓Cryo-EM ✓
5TJA5TJB5TJC5WJ55WJ9+33 more
UniProt: M0QXD0
Binding Pocket Analysis:

Structural data suggests potential allosteric modulation sites distinct from the ion conduction pore, as evidenced by ML-SA1's agonist mechanism; high-resolution structures indicate multiple druggable pockets suitable for small molecule engagement, though the exact binding mode of current agonists remains under investigation.

🧬 3D Protein Structure

🧬 MCOLN1 — PDB 5W3S Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is a key challenge given MCOLN1's structural homology to other TRP channel family members (TRPML2, TRPML3); achieving selectivity will require targeting unique structural features or allosteric sites specific to MCOLN1. Off-target effects on related ion channels could cause unwanted lysosomal dysfunction in peripheral tissues.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (1)

Relevant trials from ClinicalTrials.gov

Active
1
Completed
0
Total Enrollment
1
By Phase
PHASE1: 1
Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV Enrolling By Invitation
PHASE1 NCT07398872 n=1
Mucolipidosis Type IV
Interventions: AAV9.hMCOLN1co
Sponsor: The Children's Hospital of Zhejiang University School of Med | Started: 2026-01-13

Linked Hypotheses (1)

Lysosomal Calcium Channel Modulation Therapy0.489

Linked Experiments (2)

Live-cell microscopy of mitochondria-lysosome contacts and calcium dynamics0.900
Analysis of MLIV patient fibroblasts for contact dynamics and calcium uptake0.850

Scoring Dimensions

Portfolio 0.62 (25%) Druggability 0.41 (20%) Evidence 0.60 (20%) Safety 0.30 (15%) Competitive 0.55 (10%) Connectivity 0.90 (10%) 0.586 composite

Knowledge Graph (20)

activates (2)

MCOLN1 CALCINEURIN
MCOLN1 ATG12

associated with (15)

MCOLN1 neurodegeneration
MCOLN1 SQSTM1
MCOLN1 SOD1
MCOLN1 BCL2
MCOLN1 CTSB
...and 10 more

co discussed (3)

MCOLN1 FOXO1
MCOLN1 IGF2R
MCOLN1 RAB7A

Debate History (0)

No debates yet